Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

NCT06594432 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG: R-CHOP+Z+MTX
DRUG: R-CHOP+MTX

Sponsor

The First Affiliated Hospital with Nanjing Medical University